Clinical Trials Logo

High-Risk Cancer clinical trials

View clinical trials related to High-Risk Cancer.

Filter by:

NCT ID: NCT04334993 Recruiting - High-Risk Cancer Clinical Trials

Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

Despite recent therapeutic advancements, the outcome of young adults with Philadelphia-negative (Ph-neg) acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) remains unsatisfactory, especially in those patients with high-risk disease features. In young adults pediatric-based chemotherapy approaches improve outcome. Furthermore, there is evidence that pre-transplant antibody-based therapy may render patients with positive minimal residual disease (MRD+) to an MRD-negative status (MRD-) and that this may be associated with improved post-transplant outcome. This is prospective study to evaluate the potential benefit of a modified pediatric-based approach in young adults with Ph-neg ALL. Safety and efficacy of pre-transplant antibody-based consolidation in high-risk patients with Ph-neg ALL will be performed.

NCT ID: NCT04217356 Recruiting - Myelofibrosis Clinical Trials

Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis

ALLO-BAT
Start date: August 5, 2020
Phase:
Study type: Observational

The purpose of this research study is to see how effective hematopoietic stem cell transplantation (HCT) is compared to best available non-transplant therapies (BAT) in patients with high risk myelofibrosis. This will be done by asking participants to choose the treatment that they prefer to receive (HCT or BAT) and then comparing the outcomes of the participants in both treatment groups.

NCT ID: NCT03978663 Recruiting - Clinical trials for Locally Advanced Breast Cancer

Three Fraction Radiation to Induce Immuno-Oncologic Response

TRIO
Start date: September 2, 2020
Phase: N/A
Study type: Interventional

Patients with high risk breast cancers (any locally advanced breast cancer patient defined as Stages IIB-III [excluding inflammatory breast cancer] with stage IIA being eligible for triple negative and HER2-positive breast cancers) will receive neoadjuvant radiation to any portion of their tumour in three fractions in order to act as an immune primer. Radiation will be delivered to a portion of the tumour in three fractions. The patient will be positioned prone as per the SIGNAL 2.0 protocol. The patient will then go on to standard of care treatment (neoadjuvant chemotherapy and surgery) followed by whole-breast radiation as needed. Pathologic complete response will be the primary outcome. Immune markers will also be evaluated.